Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 124
Filtrar
Más filtros

País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Front Immunol ; 12: 765747, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34790200

RESUMEN

Biologicals are widely used therapeutic agents for rheumatologic diseases, cancers, and other chronic inflammatory diseases. They are characterized by complex structures and content of variable amounts of foreign regions, which may lead to anti-drug antibodies (ADA) development. ADA onset may limit the clinical usage of biologicals because they may decrease their safety. In fact they are mainly associated with immediate hypersensitivity reactions (HSRs). Development of ADAs is reduced by concomitant immunosuppressive treatment, while it is increased by longer intervals between drug administrations; thus, regular infusion regimens should be preferred to reduce HSRs. Once ADAs have formed, some procedures can be implemented to reduce the risk of HSRs. ADAs may belong to different isotype; the detection of IgE ADA is advisable to be assessed when high and early ADAs are detected, in order to reduce the risk of severe HRs. In patients who need to reintroduce the biological culprit, as alternative therapies are not available, drug desensitization (DD) may be applied. Desensitization should be conceptually dedicated to patients with an IgE-mediated HSR; however, it can be performed also in patients who had developed non-IgE-mediated HSRs. Although the underlying mechanisms behind successful DD has not been fully clarified, the DD procedure is associated with the inhibition of mast cell degranulation and cytokine production. Additionally, some data are emerging about the inhibition of drug-specific immune responses during DD.


Asunto(s)
Productos Biológicos/efectos adversos , Hipersensibilidad a las Drogas , Animales , Anticuerpos/inmunología , Hipersensibilidad a las Drogas/inmunología , Hipersensibilidad a las Drogas/prevención & control , Hipersensibilidad a las Drogas/terapia , Humanos
2.
Artículo en Inglés | MEDLINE | ID: mdl-33357201

RESUMEN

Vitamins are essential substances for normal cell functions, growth, and development. However, they cannot be produced by the human organism, so intake must be through the diet. Vitamin deficiency causes the onset of different diseases, ranging from pellagra to pernicious anemia, which can be corrected by reintroducing the missing vitamin form. To supply the right amount of vitamins to the body, every vitamin naturally occurring in foodstuff has been identified, extracted and synthetically produced, thus allowing either food fortification with these compounds or their pharmaceutical production. Furthermore, the increased importance attributed nowadays to body wellness and the pursuit of a permanent status of health at all costs has greatly encouraged a high consumption of vitamin supplements in modern society, since vitamin megadoses may be responsible for adverse or toxic effects. However, excessive vitamins can induce hypervitaminosis. In the USA, a national survey confirmed that 52% of adult Americans take at least one or more supplement products, vitamins and minerals being the most popular supplements in that country. Although vitamins are widespread natural substances, they may induce immediate or delayed type hypersensitivity reactions. Such adverse events are still underestimated and poorly recognized because only single cases have been reported in the literature, and no general review has yet investigated the mechanisms underlying sensitization to each vitamin, the diagnosis, and the management strategies adopted for vitamin hypersensitivity. Although delayed-type reactions to different vitamins are described in the literature, in our review, attention has been focused mainly on immediate- type reactions. Due to the importance of vitamins, further information regarding the above aspects (pathomechanisms, diagnosis and management) would be highly desirable to focus the state of the art on this particular, underestimated form of allergy, thus increasing allergists' awareness on these elusive hypersensitivity reactions.


Asunto(s)
Hipersensibilidad a las Drogas/etiología , Hipersensibilidad a los Alimentos/etiología , Vitaminas/efectos adversos , Animales , Suplementos Dietéticos/efectos adversos , Hipersensibilidad a las Drogas/clasificación , Hipersensibilidad a las Drogas/inmunología , Hipersensibilidad a los Alimentos/clasificación , Hipersensibilidad a los Alimentos/inmunología , Humanos
3.
Immunol Lett ; 226: 55-61, 2020 10.
Artículo en Inglés | MEDLINE | ID: mdl-32707128

RESUMEN

Baicalin, a component of traditional Chinese medicine, is one of the main compounds present in Scutellaria baicalensis Georgi. Pseudo-allergy induced by the injection of these medicines is a frequent adverse drug reaction. Therefore, elucidation of the anaphylactoid reaction of baicalin and its underlying mechanisms are important. Mast cells are primary effectors of allergic reactions, including pseudo-allergy. Studies have shown that Mrgprx2 in human mast cells is a specific receptor that is crucial for pseudo-allergic drug reactions, Mrgprb3 is the rat ortholog of human Mrgprx2, which in mice is designated as Mrgprb2. Here, we aimed to investigate baicalin-induced pseudo-allergy and the association of Mrgprb3 and Mrgprb2 with this effect. We examined the allergenic effect of baicalin on RBL-2H3 cells and Mrgprb3-knockdown RBL-2H3 cells. Mrgprb2-expressing HEK293 cells and Mrgprb2-knockout mice were used to evaluate the role of Mrgprb2 in baicalin-induced allergy. Baicalin was found to dose-dependently induce pseudo-allergy both in vitro and in vivo. RBL-2H3 cells were activated by baicalin, whereas in Mrgprb3-knockout RBL-2H3 cells, baicalin showed a negligible effect on cell activation. Furthermore, baicalin activated the Mrgprb2-expressing HEK293 cells. Our data showed that baicalin did not induce allergy in Mpgprb2-knockout mice. We conclude that baicalin induces pseudo-allergy via Mrgprb2 in mice.


Asunto(s)
Antiinflamatorios/uso terapéutico , Basófilos/inmunología , Hipersensibilidad a las Drogas/inmunología , Flavonoides/uso terapéutico , Receptores Acoplados a Proteínas G/metabolismo , Alérgenos/efectos adversos , Animales , Antiinflamatorios/efectos adversos , Modelos Animales de Enfermedad , Hipersensibilidad a las Drogas/etiología , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Flavonoides/efectos adversos , Técnicas de Silenciamiento del Gen , Humanos , Medicina Tradicional China , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Ratas , Receptores Acoplados a Proteínas G/genética , Transducción de Señal
5.
Expert Opin Drug Discov ; 13(5): 425-433, 2018 05.
Artículo en Inglés | MEDLINE | ID: mdl-29405076

RESUMEN

INTRODUCTION: Drug hypersensitivity reactions (DHRs) are common adverse effects of pharmaceuticals that clinically resemble allergies, and which are becoming an important burden to healthcare systems. Alongside accurate diagnostic techniques, tools which can predict potential drug-inducing hypersensitivity reactions in the pre-clinical phase are critical. Despite the important adverse reactions linked to immune-mediated hypersensitivity, at present, there are no validated or required in vivo or in vitro methods to screen the sensitizing potential of drugs and their metabolites in the pre-clinical phase. Areas covered: Enhanced prediction in preclinical safety evaluation is extremely important. The purpose of this review is to assess the state of the art of tools available to assess the allergenic potential of drugs and to highlight our current understanding of the molecular mechanisms underlying inappropriate immune activation. Expert opinion: The knowledge that allergenic drugs share common mechanisms of immune cell activation with chemical allergens, and of the definition of the mechanistic pathway to adverse outcomes, can enhance targeting toxicity testing in drug development and hazard assessment of hypersensitivity. Additional efforts and extensive resources are necessary to improve preclinical testing methodologies, including optimization, better design and interpretation of data.


Asunto(s)
Desarrollo de Medicamentos/métodos , Hipersensibilidad a las Drogas/diagnóstico , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/diagnóstico , Animales , Evaluación Preclínica de Medicamentos/métodos , Hipersensibilidad a las Drogas/inmunología , Hipersensibilidad a las Drogas/prevención & control , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/inmunología , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/prevención & control , Humanos , Pruebas de Toxicidad/métodos
6.
Clin Pharmacol Drug Dev ; 7(6): 652-660, 2018 08.
Artículo en Inglés | MEDLINE | ID: mdl-29125719

RESUMEN

Inhalational anthrax is a highly lethal infection caused by Bacillus anthracis and a serious bioterrorism threat. Protective antigen (PA) is a critical component required for the virulence of Bacillus anthracis. Obiltoxaximab, a high-affinity monoclonal antibody that neutralizes PA, is approved in the United States for intravenous use for the treatment of inhalational anthrax in combination with appropriate antibacterial drugs and for prophylaxis of inhalational anthrax when alternative therapies are not available or appropriate. Here, we explored the safety, pharmacokinetics (PK), and immunogenicity of obiltoxaximab administered by intramuscular injection at doses of 4, 8, 16, 20, and 24 mg/kg in healthy humans. Systemic exposures were approximately dose proportional, maximum serum concentrations were observed after 6-9 days, and terminal half-life ranged from 16 to 23 days. Average absolute intramuscular bioavailability was 64%. Obiltoxaximab was well tolerated, and local tolerability was acceptable up to 24 mg/kg intramuscularly, up to 6 injections per dose, and up to 5 mL per injection. No injection-site abscesses or hypersensitivity reactions occurred; no subjects developed treatment-emergent antitherapeutic antibodies over the study period of 71 days.


Asunto(s)
Anticuerpos Monoclonales/efectos adversos , Anticuerpos Monoclonales/farmacocinética , Antitoxinas/efectos adversos , Hipersensibilidad a las Drogas/inmunología , Carbunco/tratamiento farmacológico , Carbunco/inmunología , Anticuerpos Monoclonales/administración & dosificación , Antígenos Bacterianos/inmunología , Antitoxinas/administración & dosificación , Área Bajo la Curva , Bacillus anthracis/efectos de los fármacos , Bacillus anthracis/inmunología , Toxinas Bacterianas/inmunología , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Femenino , Semivida , Voluntarios Sanos , Humanos , Inyecciones Intramusculares , Masculino , Persona de Mediana Edad , Infecciones del Sistema Respiratorio/tratamiento farmacológico , Infecciones del Sistema Respiratorio/inmunología
7.
Pharmacology ; 101(1-2): 104-110, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-29136631

RESUMEN

Adverse drug reactions occur frequently and can trigger pseudoallergy, which has become a serious threat to public health. Pseudoallergy is a typical non-immune anaphylactic reaction characterized by the independence of antigen-specific immune responses. In the clinic, pseudoallergy is often elicited by the first dose of medication, and here lies its unpredictability and occasional lethal outcome. However, the mechanisms of pseudoallergy are not well understood. This review focusses on the causes and mechanisms of pseudoallergy induced by drugs. Two categories of mechanisms will be considered, namely, (1) complement activation-related pseudoallergy and (2) mast cell activation-related pseudoallergy. The factors that induce pseudoallergy include opioid drugs, complement activation-related pseudoallergenic drugs, nonsteroidal anti-inflammatory drugs and traditional Chinese medicine injections.


Asunto(s)
Hipersensibilidad a las Drogas/etiología , Activación de Complemento , Hipersensibilidad a las Drogas/inmunología , Humanos
9.
Eur Ann Allergy Clin Immunol ; 49(6): 281-283, 2017 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-29249137

RESUMEN

SUMMARY: We report the case of a 36-year-old male pharmaceutical laboratory worker. On handling Spagulax® sachets whose content is a laxative called Plantago ovata, he immediately presented rhinoconjunctivitis. Methods. Specific allergy study included SDS-PAGE with Western Blot and specific nasal challenge to Plantago ovata extract. Results. Prick by prick for Spagulax® was negative. Total IgE: 126.5 U/mL. Western Blot recognized two proteins of 15 and 20 kDa in the extract of Plantago ovata and three proteins of 15, 18 and 50 kDa in the extract of Plantago lanceolata. Conclusions. We present a case of occupational allergy due to inhalation of and/or contact with Plantago ovata seeds.


Asunto(s)
Conjuntivitis Alérgica/inducido químicamente , Hipersensibilidad a las Drogas/inmunología , Laxativos/efectos adversos , Enfermedades Profesionales/inmunología , Exposición Profesional/efectos adversos , Preparaciones de Plantas/efectos adversos , Plantago/efectos adversos , Rinitis Alérgica/inducido químicamente , Adulto , Western Blotting , Conjuntivitis Alérgica/diagnóstico , Conjuntivitis Alérgica/inmunología , Hipersensibilidad a las Drogas/diagnóstico , Industria Farmacéutica , Humanos , Inmunoglobulina E/inmunología , Pruebas Intradérmicas , Personal de Laboratorio , Masculino , Enfermedades Profesionales/diagnóstico , Preparaciones de Plantas/inmunología , Plantago/inmunología , Rinitis Alérgica/diagnóstico , Rinitis Alérgica/inmunología
10.
Immunol Allergy Clin North Am ; 37(2): 397-412, 2017 05.
Artículo en Inglés | MEDLINE | ID: mdl-28366484

RESUMEN

Biologic therapies are emerging as a significant therapeutic option for many with debilitating inflammatory and autoimmune conditions. As expansion in the number of FDA-approved agents continue to be seen, more unanticipated adverse reactions are likely to occur. Currently, the diagnostic tools, including skin testing and in vitro testing, to evaluate for immediate hypersensitivity reactions are insufficient. In this review, management strategies for common acute infusion reactions, injection site reactions, and immediate reactions suggestive of IgE-mediated mechanisms are discussed. Desensitization can be considered for reactions suggestive of IgE-mediated mechanisms, but allergists/immunologists should be involved in managing these patients.


Asunto(s)
Productos Biológicos/efectos adversos , Terapia Biológica/efectos adversos , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/etiología , Productos Biológicos/uso terapéutico , Terapia Biológica/métodos , Desensibilización Inmunológica/métodos , Manejo de la Enfermedad , Hipersensibilidad a las Drogas/diagnóstico , Hipersensibilidad a las Drogas/inmunología , Hipersensibilidad a las Drogas/terapia , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/diagnóstico , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/terapia , Humanos
11.
J Immunotoxicol ; 14(1): 31-38, 2017 12.
Artículo en Inglés | MEDLINE | ID: mdl-28121193

RESUMEN

Drug-induced liver injury (DILI) is a growing problem. Diagnostic methods to differentiate DILI caused by an adaptive immune response from liver injury of other causes or to identify the responsible drug in patients receiving multiple drugs, herbals and/or dietary supplements (polypharmacy) have not yet been established. The lymphocyte transformation test (LTT) has been proposed as a diagnostic method to determine if a subject with an apparent hypersensitivity reaction has become sensitized to a specific drug. In this test, peripheral blood mononuclear cells (PBMC) collected from a subject are incubated with drug(s) suspected of causing the reaction. Cell proliferation, measured by the incorporation of [3H]-thymidine into new DNA, is considered evidence of a drug-specific immune response. The objectives of the current studies were to: (1) develop and optimize a modified version of the LTT (mLTT) and (2) investigate the feasibility of using the mLTT for diagnosing DILI associated with an adaptive immune response and identifying the responsible drug. PBMC collected from donors with a history of drug hypersensitivity reactions to specific drugs (manifested as skin rash) were used as positive controls for assay optimization. Following optimization, samples collected from 24 subjects enrolled in the U.S. Drug-Induced Liver Injury Network (DILIN) were tested in the mLTT. Using cytokine and granzyme B production as the primary endpoints to demonstrate lymphocyte sensitization to a specific drug, most samples from the DILIN subjects failed to respond. However, robust positive mLTT responses were observed for two of four samples from three DILIN subjects with hepatitis due to isoniazid (INH). We conclude that the mLTT, as performed here on frozen and thawed PBMC, is not a reliable test for diagnosing DILI caused by all drugs, but that it may be useful for confirming the role of the adaptive immune response in DILI ascribed to INH.


Asunto(s)
Enfermedad Hepática Inducida por Sustancias y Drogas/diagnóstico , Hipersensibilidad a las Drogas/diagnóstico , Hepatitis/diagnóstico , Pruebas Inmunológicas/métodos , Isoniazida/efectos adversos , Leucocitos Mononucleares/inmunología , Activación de Linfocitos , Enfermedad Aguda , Inmunidad Adaptativa , Proliferación Celular , Células Cultivadas , Enfermedad Hepática Inducida por Sustancias y Drogas/inmunología , Citocinas/metabolismo , Diagnóstico Diferencial , Hipersensibilidad a las Drogas/inmunología , Estudios de Factibilidad , Estudios de Seguimiento , Granzimas/metabolismo , Hepatitis/inmunología , Humanos , Isoniazida/uso terapéutico , Leucocitos Mononucleares/efectos de los fármacos
14.
Cell Host Microbe ; 19(6): 865-73, 2016 Jun 08.
Artículo en Inglés | MEDLINE | ID: mdl-27237365

RESUMEN

Compared to bacteria, the role of fungi within the intestinal microbiota is poorly understood. In this study we investigated whether the presence of a "healthy" fungal community in the gut is important for modulating immune function. Prolonged oral treatment of mice with antifungal drugs resulted in increased disease severity in acute and chronic models of colitis, and also exacerbated the development of allergic airway disease. Microbiota profiling revealed restructuring of fungal and bacterial communities. Specifically, representation of Candida spp. was reduced, while Aspergillus, Wallemia, and Epicoccum spp. were increased. Oral supplementation with a mixture of three fungi found to expand during antifungal treatment (Aspergillus amstelodami, Epicoccum nigrum, and Wallemia sebi) was sufficient to recapitulate the exacerbating effects of antifungal drugs on allergic airway disease. Taken together, these results indicate that disruption of commensal fungal populations can influence local and peripheral immune responses and enhance relevant disease states.


Asunto(s)
Antifúngicos/efectos adversos , Disbiosis/inducido químicamente , Disbiosis/inmunología , Hongos/efectos de los fármacos , Hongos/inmunología , Intestinos/microbiología , Anfotericina B/efectos adversos , Anfotericina B/farmacología , Animales , Antifúngicos/farmacología , Bacterias/efectos de los fármacos , Secuencia de Bases , Colitis/inmunología , Colitis/microbiología , Suplementos Dietéticos , Hipersensibilidad a las Drogas/inmunología , Hipersensibilidad a las Drogas/microbiología , Fluconazol/efectos adversos , Fluconazol/farmacología , Hongos/genética , Microbioma Gastrointestinal/efectos de los fármacos , Microbioma Gastrointestinal/inmunología , Hipersensibilidad/inmunología , Hipersensibilidad/microbiología , Ratones , Ratones Endogámicos C57BL
15.
J Immunotoxicol ; 13(4): 535-47, 2016 07.
Artículo en Inglés | MEDLINE | ID: mdl-27043250

RESUMEN

The development of immune-dependent drug hypersensitivity reactions (IDHR) is likely to involve activation of the innate immune system to stimulate neo-antigen specific T-cells. Previously it has been shown that, upon oral exposure to several drugs with immune-adjuvant capacity, mice developed T-cell-dependent responses to TNP-OVA. These results were indicative of the adjuvant potential of these drugs. The present study set out to evaluate the nature of this adjuvant potential by focusing on early immune changes in the spleen, by testing several drugs in the same experimental model. Mice were exposed to one or multiple oral doses of previously-tested drugs: the non-steroidal-anti-inflammatory drug (NSAID) diclofenac (DF), the analgesic acetaminophen (APAP), the anti-epileptic drug carbamazepine (CMZ) or the antibiotic ofloxacin (OFLX). Within 24 h after the final dosing, early innate and also adaptive immune parameters in the spleen were examined. In addition, liver tissue was also evaluated for damage. Exposure to APAP resulted in severe liver damage, increased levels of serum alanine aminotransferase (ALT) and local MIP-2 expression. DF exposure did not cause visible liver damage, but did increase liver weight. DF also elicited clear effects on splenic innate and adaptive immune cells, i.e. increased levels of NK cells and memory T-cells. Furthermore, an increase in plasma MIP-2 levels combined with an influx of neutrophils into the spleen was observed. OFLX and CMZ exposure resulted in increased liver weights, MIP-2 expression and up-regulation of co-stimulatory molecules on antigen-presenting cells (APC). The data suggested that multiple immune parameters were altered upon exposure to drugs known to elicit immunosensitization and that broad evaluation of immune changes in straightforward short-term animal models is needed to determine whether a drug may harbor the hazard to induce IDHR. The oral exposure approach as used here may be applied in the future as an immunotoxicological research tool in this type of evaluation.


Asunto(s)
Hipersensibilidad a las Drogas/inmunología , Inmunidad Innata , Factores Inmunológicos/uso terapéutico , Células Asesinas Naturales/efectos de los fármacos , Hígado/efectos de los fármacos , Bazo/efectos de los fármacos , Linfocitos T/inmunología , Acetaminofén/administración & dosificación , Acetaminofén/efectos adversos , Inmunidad Adaptativa/efectos de los fármacos , Administración Oral , Animales , Carbamazepina/administración & dosificación , Carbamazepina/efectos adversos , Células Cultivadas , Diclofenaco/administración & dosificación , Diclofenaco/efectos adversos , Femenino , Humanos , Inmunidad Innata/efectos de los fármacos , Factores Inmunológicos/efectos adversos , Memoria Inmunológica , Células Asesinas Naturales/inmunología , Hígado/patología , Ratones , Ratones Endogámicos C3H , Ofloxacino/administración & dosificación , Ofloxacino/efectos adversos , Bazo/inmunología , Linfocitos T/efectos de los fármacos
16.
Anaesthesiol Intensive Ther ; 48(2): 128-34, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-26977853

RESUMEN

Using local anaesthetics in daily practice, particularly by anaesthetists and dentists, is connected with the risk of side effects. Therefore, the observation of side effects, carrying out detailed research (according to the chart proposed in this study) and conducting specialist examinations is of the highest importance. There is a variety of side effects that could occur during local anaesthesia procedures, with the intensity ranging from clinically unimportant to life threatening. Clinicians' major concerns are the appearance of various hypersensitivity reactions, including anaphylaxis. Healthcare providers responsible for the administration of local anaesthetics should be able to detect hypersensitivity reactions to implement appropriate treatment and then choose highly selected diagnostic procedures. The final diagnosis should be based on specific medical history; documentation, including a description of the case and measurement of tryptase activity; skin tests; and provocation trials. Screening tests are not recommended in populations without hypersensitivity to local anaesthestics in their medical history.


Asunto(s)
Anestésicos Locales/efectos adversos , Hipersensibilidad a las Drogas/terapia , Anestesia Local/efectos adversos , Hipersensibilidad a las Drogas/epidemiología , Hipersensibilidad a las Drogas/inmunología , Humanos
17.
Zhongguo Zhong Yao Za Zhi ; 41(2): 345-349, 2016 Jan.
Artículo en Chino | MEDLINE | ID: mdl-28861984

RESUMEN

The (anaphylactoid) hypersensibility mechanism of ″imprinting templates″ characteristics of traditional Chinese medicine (TCM) injection supramolecules was clarified to lay the foundation to build safety evaluation method. Based on the previous publication on special impact of Chinese medicine theories on supramolcular chemistry, combined with the natural origination of (anaphylactoid) hypersensitized special rules as well as the sensitization phenomenon of cordate houttuynia injection, the impact of the structure characteristics of ″imprinting templates″ in TCM injection supramolecules on its (anaphylactoid) hypersensibility was clarified. In Chinese medicine injections, the supramolecular structures can independently be generated, showing overall apparent (anaphylactoid) hypersensibility nature, and their structure characteristics were dependent on the strength. In addition, (anaphylactoid) hypersensitive critical supramolecular structure was present. When it was administrated by ″injection″, it's structure was not easy to be destroyed, often showing apparent immunogenicity, whereas if it was administrated by ″oral″, the structure would be destroyed by the gastrointestinal tract, showing weaker or no apparent immunogenicity. Therefore, there are differences in (anaphylactoid) hypersensibility between ″injection″ and ″oral″ administration of TCM. TCM injections would produce the supramolecules between ″molecular society″ by independent reaction of supramolecular ″imprinting template″ (chemical determinants), showing apparent immune process of recognition, copying, and storage. Single molecule is a special example for this. The screening of anaphylactoid (sensitinogen) includes the single ingredients and their forming supramolecules for TCM injection. This is the unique feature for safety evaluation of Chinese medicine injection.


Asunto(s)
Hipersensibilidad a las Drogas/etiología , Medicamentos Herbarios Chinos/efectos adversos , Medicamentos Herbarios Chinos/síntesis química , Hipersensibilidad a las Drogas/inmunología , Medicamentos Herbarios Chinos/administración & dosificación , Humanos , Inyecciones , Medicina Tradicional China , Impresión Molecular
20.
Int Immunopharmacol ; 28(2): 945-51, 2015 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-25939534

RESUMEN

Sinomenine (SIN), an alkaloid derived from the Chinese medicinal plant Sinomenium acutum, is the major component of Zhengqing Fongtong Ning (ZQFTN), a pharmaceutical drug produced by Hunan Zhengqing Pharmaceutical Co. Ltd. in China for the treatment of rheumatoid arthritis and other autoimmune diseases. Some clinic reports indicate that ZQFTN may induce an anaphylactic reaction via potentiating the degranulation of immune cells. In the current study, we aimed to examine whether SIN is capable of inducing the degranulation of basophilic leukemia 2H3 (RBL-2H3) cells to elucidate how the anaphylactic reaction occurs. The results revealed that SIN could up-regulate ß-hexosaminidase levels in RBL-2H3 cells without significant cytotoxicity, suggesting that SIN could induce the degranulation of RBL-2H3 cells. Furthermore, SIN increased the release of prostaglandin D2 (PGD2) and prostaglandin E2 (PGE2) in RBL-2H3 cells via promoting the expression of phosphorylated-extracellular signal-regulated kinase (P-ERK), the cleavage of Annexin A1 (ANXA1), and phosphorylated-cytosolic phospholipase A2 (P-cPLA2), as well as cyclooxygenase-2 (COX-2). The ERK inhibitor, PD98059, significantly attenuated the up-regulatory effect of SIN on cPLA2 phosphorylation. Interestingly, SIN did not significantly increase Ca(2+) influx in the cells. These findings not only explored the anaphylactic reaction and underlying mechanism of ZQFTN in RBL-2H3 cells, but may promote the development of relevant strategies for overcoming the adverse effects of the drug.


Asunto(s)
Anafilaxia/prevención & control , Artritis Reumatoide/tratamiento farmacológico , Basófilos/efectos de los fármacos , Hipersensibilidad a las Drogas/inmunología , Morfinanos/farmacología , Anafilaxia/etiología , Animales , Anexina A1/metabolismo , Artritis Reumatoide/complicaciones , Basófilos/inmunología , Calcio/metabolismo , Degranulación de la Célula/efectos de los fármacos , Línea Celular , Hipersensibilidad a las Drogas/complicaciones , Humanos , Sistema de Señalización de MAP Quinasas/efectos de los fármacos , Morfinanos/efectos adversos , Fosfolipasas A2/metabolismo , Fosforilación/efectos de los fármacos , Ratas , Sinomenium/inmunología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA